Progenics Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of therapeutic products for the treatment of unmet medical needs of patients with debilitating conditions and life-threatening diseases in the United States. It primarily focuses on the areas of gastroenterology, virology, and oncology. The company's development programs and product candidates include methylnaltrexone-subcutaneous, which completed Phase 3 clinical trial for the treatment of opioid-induced constipation; methylnaltrexone-intravenous, which is under Phase 3 clinical trial for the management of post-operative ileus; and Methylnaltrexone-Oral, a Phase 2 clinical trial oral form for the treatment of opioid-induced constipation. It is also developing PRO 140 Phase 1b clinical trial, designed to block HIV infection by inhibiting virus-cell binding; ProVax, a vaccine product candidate for the prevention of HIV infection or therapeutic treatment for HIV-positive individuals; and GMK Vaccine, a therapeutic vaccine, which is in Phase 3 clinical trial for the prevention of recurrence of melanoma. In addition, the company engages in a research program to discover treatments for hepatitis C, a chronic liver disease that block viral entry into cells. Further, Progenics Pharmaceuticals, through a joint venture with Cytogen Corporation, is developing in vivo immuno-therapies for treatment of prostate cancer, including a human monoclonal antibody-drug conjugate directed against prostate-specific membrane antigen (PSMA). The company's PSMA vaccine is in Phase 1 clinical testing. It has a collaboration agreement with Wyeth Pharmaceuticals to develop and commercialize subcutaneous, intravenous, and oral forms of methylnaltrexone. The company was incorporated in 1986 and is based in Tarrytown, New York.